Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements

Next Previous
X
Search
Trial Profile

Phase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevantolol (Primary)
  • Indications Huntington's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors SOM Biotech

    • Most Recent Events

    • 09 Dec 2022 Results assessing the efficacy and safety of SOM3355 with recently identified VMAT2 inhibitory properties, as a repositioned treatment to reduce chorea in Huntington's disease, published in the British Journal of Clinical Pharmacology.
    • 05 Oct 2021 Results presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
    • 04 Oct 2021 According to a SOM Biotech media release, data from this study will be presented at the 34th ECNP Congress, 2021 in Lisbon, Portugal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top